盐酸羟考酮控释片治疗中度神经病理性癌痛的获益分析

摘要

Objective To approach the efficacy and feasibility of the treatment of mezzo neuropathic cancer pain with Oxycodone hydrochloride controlled-release tablets. Methods Patients with mezzo neuropathic cancer pain (n=66) were randomly divided into two groups.Oxycodone hydrochloride controlled-release tablets were took orally in group A, and tramadol hydrochloride sustained-release tablets were took orally in group B.The difference of pain intensity, life quality, remission rate of pain and the adverse reaction were contrast between the two groups before and after the treatments. Results The numerical rating scale (NRS) score of group A was lower than group B on the 1st, 2nd day after the treatments (P<0.05). On the contrary, the Karnofsky (KPS) score of group A was higher than group B at the same time(P<0.05). The remission rate of pain was 93.9% in group A on the 1st day after the treatments, which was 18.2% in group B. The difference was obvious extremely(P<0.01).The main adverse reactions included constipation,dizziness, nausea and vomiting. The incidence rates of the latter two were different obviously from each other between the two groups(the rate of group A was lower than group B,P<0.05). Conclusion Oxycodone hydrochloride controlled-release tablets is pretty effective and feasible clinically in the treatment of mezzo neuropathic cancer pain.%　　目的探讨对中度神经病理性癌痛应用盐酸羟考酮控释片的有效性和可行性。方法66例中度神经病理性癌痛的患者，随机分为两组，分别口服盐酸羟考酮控释片（A 组）和盐酸曲马多缓释片（B 组），比较治疗后两组间疼痛强度、生活质量、疼痛缓解率和不良反应的差异。结果治疗后1d、2d 的 NRS 评分 A 组低于 B 组（P ＜0.05），同期的 KPS 评分 A 组高于 B 组（P ＜0.05）。A 组治疗后1d 的疼痛缓解率为93.9%，B 组为18.2%，差异极其明显（P ＜0.01）。不良反应主要为便秘、头晕和恶心呕吐，后两者的发生率在两组的对比差异明显（A组低于 B 组，P ＜0.05）。结论盐酸羟考酮控释片治疗中度神经病理性癌痛临床效果好，可行性强。